Two Different Purchases, Sold From the Same Shelf

I want to start by saying what this article is not. It is not going to lecture anyone about self-acceptance. I run a publication about elective aesthetics; I have spent a frankly ridiculous amount of money on things that were not medically necessary, and I am not going to develop principles about somebody else’s face that I do not apply to my own.

What I am going to do is separate two purchases that get sold as one, because the evidence, the risk profile, the endpoint and the exit are different for each, and being clear about which you are making is the whole of the useful advice here.

Purchase one: a pigment disorder with a name

Melasma. Post-inflammatory hyperpigmentation from acne, an ingrown hair, a burn, a bug bite. Solar lentigines. These have diagnoses, defined endpoints, and an evidence base — thinner than it should be, but real.

The endpoint is the thing to notice. You are returning a patch of skin to the color of the skin around it. There is a target, you can see when you have hit it, and you stop.

What has evidence behind it, honestly graded:

Oral tranexamic acid has the best recent data in melasma. A network meta-analysis published in the Indian Journal of Dermatology, Venereology and Leprology in 2023 pooled 599 patients across six randomized trials, drawn from 92 identified studies, and landed on an optimal dose of 250 mg three times daily for twelve weeks, with 250 mg twice daily as an acceptable option for patients who struggle with adherence. The clotting question — tranexamic acid is an antifibrinolytic, so the concern is not imaginary — was examined in a multicenter propensity-score-matched electronic health record cohort published in 2025, which found no association with thromboembolism at melasma dosing. This is a prescription decision and a conversation with a prescriber who knows your history, not a supplement purchase.

Thiamidol — isobutylamido thiazolyl resorcinol — has gone head to head with 4 percent hydroquinone in an evaluator-blinded randomized trial and been through a 24-week randomized, double-blind, vehicle-controlled study with a regression phase. That is a more serious evidence package than almost anything else in the category, and it is available without a prescription.

Azelaic acid, cysteamine, kojic acid, niacinamide, retinoids and arbutin all appear across the melasma treatment reviews as evidenced adjuncts. The quality varies considerably between them and I am not going to pretend a niacinamide serum and a prescription retinoid are the same class of intervention.

And the thing that outranks all of them: whatever is causing the pigment. Melasma responds to visible light, which means a tinted sunscreen containing iron oxides is doing more for it than most of the actives in this list. PIH responds to the acne that caused it. Treating the mark while the cause keeps running is the most expensive way to stand still, and it is what most routines are actually doing.

One more finding that deserves to be better known, from the same literature: melasma clusters in Fitzpatrick III to V, not VI. In a database study of 41,283 melasma patients, Asian patients carried an odds ratio of 2.0 and Hispanic patients 1.3 — while Black and African American patients sat at 0.8, which is exactly where white patients sat. The authors read this as supporting a preference for melanized phenotypes in the middle of the range and less so at either extreme. The mental model that says more pigment means more melasma runs out at the deep end.

Purchase two: making healthy skin lighter than it is

Different product entirely, even when the ingredient list overlaps.

There is no endpoint here, which is the structural problem. Uniform skin is an achievable target; lighter skin is a direction. A direction does not tell you when to stop, and a product used without a stopping condition is used for years, which is exactly the exposure pattern that produces exogenous ochronosis at 2 percent hydroquinone, striae from clobetasol, and mercury accumulation.

The scale of this is not a niche concern. The global skin-lightening products market was valued at around 11.2 billion dollars in 2023 and is projected past 13 billion by 2026, with the Asia-Pacific region holding more than half the revenue. A 2019 meta-analysis put global lifetime prevalence of skin bleaching at roughly 30 percent — 43.8 percent among women.

Country-level prevalence figures circulate alongside that meta-analysis, several of them very high, and I am not printing them here. I could not get from the number to the survey that produced it, and a percentage attached to a country is the kind of figure that gets quoted for a decade by people who will never check it. The pooled figure is sourced. Take that one.

Even so: a lifetime prevalence near a third is not the number of a fringe practice. That is a mass market, and it is served overwhelmingly by unregulated products, because the regulated ones are prescription-only and indicated for something else.

The mirror, which I am including deliberately

Because I do not think this is a story about other people’s choices.

The same impulse running in the opposite direction is the tanning industry, and its harm data is the cleanest in this entire field. Lazovich and colleagues, 1,167 melanoma cases against 1,101 controls: ever-use of indoor tanning, odds ratio 1.74. Fifty or more hours of use, 3.18. High-pressure devices, 4.44. IARC classifies UV-emitting tanning devices as Group 1 carcinogens — the same category as tobacco.

Fair-skinned women have been damaging themselves to look darker for fifty years, in regulated commercial premises, at scale, with clearer evidence of harm than anything in the lightening literature. Nobody writes think-pieces about their self-esteem. They get a warning label and a sign-in sheet.

I mention it because the asymmetry in how these two markets get discussed is not about risk. It is about who is doing it.

The health consequences of colorism are, for what it is worth, now measurable. Cobb and colleagues, working with National Survey of American Life data, found perceived in-group colorism associated with any lifetime psychiatric disorder at an adjusted odds ratio of 1.20, with significant associations for anxiety, alcohol use, substance use and eating disorders. That is a social determinant with an odds ratio attached, which is a fairly recent development in this literature and worth knowing exists.

So which purchase is this

Three questions, and I would ask them before the ingredient list.

Does the thing you are treating have edges? A patch, a mark, a cheek that does not match the jaw — that is a target and it has a finish line. “My skin generally” does not.

Would you know when to stop? If the answer is when it looks right, and there is no reference point for right, you are buying purchase two whatever the label says.

What happens when you run out? A treatment for a disorder ends and the skin holds, with maintenance against the cause. Depigmented skin returns to its own color when you stop, which means the product is not a course, it is a subscription — and a subscription to something that accumulates in your kidneys is a different proposition to a subscription to a moisturizer.

Nobody has to justify their answer to me. But the shelf will not sort this for you, and the risk lands very differently depending on which one you are actually holding.

One cause worth ruling out before buying either is in the cupboard rather than on the shelf. Several common medicines carry strong pigmentation signals and, in the largest recent analysis, a substantial proportion of them carry no labeling for it — which is why the leaflet is not the last word.

This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.